Predictions
Klöckner & Co SE
Start price
Target price
Perf. (%)
€10.25
08.02.22
08.02.22
€17.00
31.03.24
31.03.24
-33.76%
01.04.24
01.04.24
Very high dividend yield expected
Revenue growth > 30% per year expected
Market Leader or Top 3
Significant cyclical dependencies
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€144.95
10.02.24
10.02.24
€147.00
10.02.25
10.02.25
5.07%
29.03.24
29.03.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Deutsche Pfandbriefbank AG
Start price
Target price
Perf. (%)
€4.53
16.03.24
16.03.24
€5.00
16.03.25
16.03.25
6.18%
27.03.24
27.03.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
Süss MicroTec SE
Start price
Target price
Perf. (%)
€22.70
13.11.23
13.11.23
-
13.11.24
13.11.24
68.28%
27.03.24
27.03.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Hornbach Holding AG & Co. KGaA
Start price
Target price
Perf. (%)
€69.75
27.02.24
27.02.24
€72.00
27.02.25
27.02.25
6.38%
26.03.24
26.03.24
STO SE & Co. KGaA
Start price
Target price
Perf. (%)
€143.20
25.02.24
25.02.24
€154.00
01.04.24
01.04.24
7.68%
25.03.24
25.03.24
Dermapharm Holding SE
Start price
Target price
Perf. (%)
€40.98
28.11.23
28.11.23
€48.00
28.11.25
28.11.25
-19.28%
25.03.24
25.03.24
Could be worthwhile Investment >10% per year
Undervalued
PVA TePla AG
Start price
Target price
Perf. (%)
€18.82
28.11.23
28.11.23
€30.00
28.11.25
28.11.25
7.44%
25.03.24
25.03.24
Strong uniques
Differentiated customer and product portfolio
Growths faster than the competition
Market Leader or Top 3
Deutsche Pfandbriefbank AG
Start price
Target price
Perf. (%)
€3.85
02.03.24
02.03.24
-
02.03.25
02.03.25
17.73%
16.03.24
16.03.24
Deutsche Pfandbriefbank AG
Start price
Target price
Perf. (%)
€6.28
31.10.23
31.10.23
€6.00
31.10.24
31.10.24
-27.84%
16.03.24
16.03.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued